Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 665Neoplasms 585Colorectal Neoplasms 291Carcinoma, Non-Small-Cell Lung 289Prostatic Neoplasms 277Lung Neoplasms 217Melanoma 159Multiple Myeloma 149Neoplasm Metastasis 145Head and Neck Neoplasms 143Pancreatic Neoplasms 139Ovarian Neoplasms 129Carcinoma, Hepatocellular 126Leukemia, Myeloid, Acute 121Brain Neoplasms 111Squamous Cell Carcinoma of Head and Neck 109Colonic Neoplasms 109Uterine Cervical Neoplasms 106Stomach Neoplasms 102Recurrence 101Lymphoma 100Glioblastoma 90Lymphoma, Non-Hodgkin 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 78Hematologic Neoplasms 78Lymphoma, Follicular 77Urinary Bladder Neoplasms 76Parkinson Disease 4, Autosomal Dominant Lewy Body 74Glioma 72Sarcoma 70

Interventions

olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Ovarian × 1 year × Clear all
NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

AstraZeneca

Phase 2 Completed
298 enrolled 18 charts
BreastGastrointestinalGenitourinaryGynecologic

Ovarian

Data powered by HemOnc (CC BY 4.0) Colophon âš¡